HER2-Targeted Therapy Reduces Incidence and Progression of Midlife Mammary Tumors in Female Murine Mammary Tumor Virus huHER2-Transgenic Mice

Clinical Cancer Research

Volumn 10, Issue 7, 2004, Pages 2499-2511

  Finkle, David ^a   Quan, Zhi Ricky ^a   Asghari, Vida ^a   Kloss, Jessica ^a   Ghaboosi, Nazli ^a   Mai, Elaine ^a   Wong, Wai Lee ^a   Hollingshead, Philip ^a   Schwall, Ralph ^a   Koeppen, Hartmut ^a   Erickson, Sharon ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HERPES SIMPLEX VIRUS GLYCOPROTEIN D ANTIBODY; MU4D5; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST TUMOR; CANCER INCIDENCE; CONTROLLED STUDY; DRUG TARGETING; FEMALE; GENE OVEREXPRESSION; HARDER GLAND; MAMMARY GLAND; MOUSE; NONHUMAN; ONCOVIRINAE; PRIORITY JOURNAL; PROMOTER REGION; TRANSGENIC MOUSE; TUMOR GROWTH;

ANIMALS; ANTIBODIES, MONOCLONAL; BASE SEQUENCE; DISEASE PROGRESSION; DOWN-REGULATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; MAMMARY NEOPLASMS, ANIMAL; MAMMARY TUMOR VIRUS, MOUSE; MICE; MICE, TRANSGENIC; MODELS, GENETIC; MOLECULAR SEQUENCE DATA; NEOPLASM METASTASIS; NEOPLASMS, EXPERIMENTAL; PROMOTER REGIONS (GENETICS); RECEPTOR, ERBB-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; RNA, MESSENGER; TIME FACTORS; TRANSGENES;

EID: 11144354476     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-03-0448     Document Type: Article

References (33)

1. Slamon D, Clark G, Wong S, Levin W, Ullrich A, McGuire W. Human breast cancer: correlation of relapse and survival with amplification of the HER2-neu oncogene. Science (Wash. DC) 1987;235:177-82.
2. Slamon D, Godolphin W, Jones L, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science (Wash. DC) 1989;244:707-12.
3. Weiner DB, Liu J, Cohen J, Williams W, Greene MI. A point mutation in the neu oncogene mimics ligand induction of receptor aggregation. Nature (Lond.) 1989;339:230-1.
4. Pinkas-Kramarski R, Alroy I, Yarden Y. ErbB receptors and EGF-like ligands: cell lineage determination and oncogenesis through combinatorial signaling. J. Mammary Gland Biol Neoplasia 1997;2:97-107.
5. Adams JM, Harris AW, Pinkert CA, et al. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature (Lond.) 1985;318:533-8.
6. Brinster RL, Cheu HY, Messing A, van Dyke T, Levine AJ, Palmiter RD. Transgenic mice harboring SV40 T-antigen genes develop characteristic brain tumors. Cell 1984;37:367-79.
7. Hanahan D. Heritable-formation of pancreatic β cell tumors in transgenic mice expressing recombinant insulin/SV40 oncogenes. Nature (Lond.) 1986;315:115-22.
8. Muller WJ, Sinn E, Pattentale PK, Wallace R, Leder P. Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell 1988;54:105-15.
9. Stewart TA, Pattengale PK, Leder P. Spontaneous mammary adenocarcinomas in transgenic mice that carry and express MTV/myc fusion genes. Cell 1984;38:627-37.
10. Guy CT, Webster MA, Schaller M, Parsons TJ, Cardiff RD, Muller WJ. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci USA 1992;89:10578-82.
11. Bargmann CI, Weinberg RA. Oncogenic activation of the neuencoded receptor protein by point mutation and deletion. EMBO J 1988;7:2043-52.
12. Bouchard L, Lamarre L, Tremblay PJ, Jolicoeur P. Stochastic appearance of mammary tumors in transgenic mice carrying the MMTV/c-neu oncogene. Cell 1989;57:931-6.
13. 659). EMBO J 1990;9:181-90.
14. Leyland-Jones B, Smith I. Role of Herceptin in primary breast cancer: views from North America and Europe. Oncology 2001;61:83-91.
15. Sarup JC, Johnson RM, King KL, et al. Characterization of an anti-p185HER2 monoclonal antibody that stimulates receptor function and inhibits tumor cell growth. Growth Regul 1991;1:72-82.
16. Sliwkowski MX, Lofgren JA, Lewis GD, Hotaling TE, Fendly BM, Fox JA. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol 1999;26(Suppl 12) 60-70.
17. Lewis GD, Figari I, Fendly B, et al. Differential responses of human tumor cell lines to anti-p185 HER2 monoclonal antibodies. Cancer Immunol Immunother 1993;37:255-63.
18. Child SJ, Miller MK, Geballe AP. Translational control by an upstream open reading frame in the HER2/neu transcript. J Biol Chem 1999;274:24335-41.
19. Taketo M, Schroeder AC, Roderick TH, et al. FVB/N: An inbred mouse strain preferable for transgenic analysis. Proc Natl Acad Sci USA 1991;88:2065-9.
20. Hogan B, Costantini F, Lacy E. Manipulating the mouse embryo: a laboratory manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press. 1986.
21. Rao GN, Ney E, Herbert RA. Influence of diet on mammary cancer in transgenic mice bearing an oncogene expressed in mammary tissue. Breast Cancer Res Treat 1997;45:149-58.
22. Sias PE, Kotts CE, Vetterlein D, Shepard M, Wong WLT. ELISA for quantitation of the extracellular domain of p185 HER2 in biological fluids. J Immunol Meth 1990;132:73-80.
23. Gerlai R, Pisacane P, Erickson S. Heregulin, but not ErbB2 or ErbB3, heterozygous mutant mice exhibit hyperactivity in multiple behavioral tasks. Behav Brain Res 2000;109:219-27.
24. Heng HHQ, Squire J, Tsui L-C. High resolution mapping of mammalian genes by in situ hybridization to free chromatin. Proc Natl Acad Sci USA 1992;89:9509-13.
25. Heng HHQ, Tsui L-C. Modes of DAPI banding and simultaneous in situ hybridization. Chromosoma 1993;102:325-32.
26. Fendly, B. M., Kotts, C. E., Wong, W. L. T., et al. Successful immunization of rhesus monkeys with the extracellular domain of p 185 HER2: a potential approach to human breast cancer. Vaccine Res 1993;2:129-39.
27. Cox DR, Oakes D. Analysis of survival data. London: Chapman and Hall. 1984.
28. Brodie SG, Xu X, Li C, Kuo A, Leder P, Deng C-X. Inactivation of p53 tumor suppressor gene acts synergistically with c-neu oncogene in salivary gland tumorigenesis. Oncogene 2001;20:1445-54.
29. Krinke G, Fix A, Jacobs M, Render J, Weisse I. Eye and Harderian gland. In: Mohr U, editor. International classification of rodent tumors: the mouse. New York: Springer-Verlag. 2001; p. 347-59.
30. Chan R, Muller WJ, Siegel PM. Oncogenic activating mutations in the neu/ErbB2 oncogene are involved in the induction of mammary tumors. Ann NY Acad Sci 1999;889:45-51.
31. Muller WJ, Ho J, Siegel PM. Oncogenic activation of Neu/ErbB2 in a transgenic mouse model for breast cancer. Biochem Soc Symp 1998; 63:149-57.
32. Siegel PM, Dankort DL, Hardy WR, Muller WJ. Novel activating mutations in the neu proto-oncogene involved in induction of mammary tumors. Mol Cell Biol 1994;14(11):7068-77.
33. Crone SA, Zhao Y-Y, Fan L, et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med 2002;8:459-65.